Summary Serum-free supernatants from in vitro maintained gastrointestinal cancer and melanoma cell lines inhibit the generation of lymphokine (IL-2) activated killer (LAK) Lafreniere et al., 1985; Mule et al., 1986b; Rosenberg et al., 1986) . Unfortunately this experience is not paralleled by the clinical application of such an approach where some 60% of patients with metastatic disease fail to respond to this therapy West et al., 1987; Topalian et al., 1988) . Similarly, treatment with IL-2 alone appears to be ineffective (Lotze et al., 1986) despite the fact that many human tumours are infiltrated by host mononuclear cells which might become cytotoxic following exposure to IL-2 in vivo (Svennevig et al., 1984; Cozzolino et al., 1986) .
Under certain circumstances lymphocytes derived from the peripheral blood (PBL) or from tumour-infiltrating leukocyte (TIL) populations become highly cytotoxic towards tumour cells on exposure to the T-cell derived lymphokine, interleukin 2 (IL-2) (Grimm et al., 1982; Phillips et al., 1986; Roberts et al., 1987) . In the case of PBL the cytotoxicity is non-MHC-restricted and the cytotoxic cell precursors are mainly derived from cells expressing the phenotype of natural killer cells (Ortaldo et al., 1986; Roberts et al., 1987) , and are termed lymphokine-activated killer (LAK) cells following exposure to IL-2. In contrast the cytotoxicity exerted by lymphocytes derived from TIL may be MHCrestricted and such cells possess T-cell characteristics Whiteside et al., 1988) . Adoptive cellular immunotherapy with either syngeneic LAK or TIL cells expanded in vitro with IL-2 causes the regression of established metastases in a wide variety of murine tumour models (Eberlein et al., 1982; Lafreniere et al., 1985; Mule et al., 1986b; Rosenberg et al., 1986) . Unfortunately this experience is not paralleled by the clinical application of such an approach where some 60% of patients with metastatic disease fail to respond to this therapy West et al., 1987; Topalian et al., 1988) . Similarly, treatment with IL-2 alone appears to be ineffective (Lotze et al., 1986) despite the fact that many human tumours are infiltrated by host mononuclear cells which might become cytotoxic following exposure to IL-2 in vivo (Svennevig et al., 1984; Cozzolino et al., 1986) .
Prompted by the observations that both IL-2 production and LAK cell generation were impaired with patients with tumours which had extended beyond local confines (Monson et al., 1986 (Monson et al., , 1987 , we have previously shown that the presence of low numbers of some cell-line derived tumour cells was found to potently inhibit LAK cell generation in vitro (Guillou et al., 1989) . A number of reports have demonstrated that supernatants derived from tumour cell lines can inhibit lymphocyte proliferation and cytokine production (Werkmeister et al., 1980; Meischner et al., 1986; Ebert et al., 1987; Pommier et al., 1987; Farram et al., 1982; Hersey et al., 1983) . However, the effects of these supernatants on the generation of cytotoxic responses has rarely been examined (Cozzolino et al., 1987 33258 . In experiments in which the tumour cells were added directly to the LAK generation cultures, they were obtained from the confluent monolayers after a brief trypsinisation followed by six washes in complete medium, before re-suspension at a cell density appropriate to a final lymphocyte:tumour cell ratio of 50:1, as previously described (Guillou et al., 1989 Cytotoxicity assay This was a standard 4 h 5"Cr release assay as previously described (Monson et al., 1987) . Doubling dilutions of 5 x 105 effector cells in 0.1 ml complete medium were added to 104 51Cr-labelled target cells in 0.1ml complete medium in triplicate round-bottomed microtitre wells. After 4 h 100 ul of the supernatant was harvested from each well and the radioactivity counted in a gamma-counter. The percentage specific 51Cr release at each effector:target cell ratio was calculated as previously described. Data Moreover, the presence of 20% serum-free supernatant from the suppressive cell lines was also highly suppressive of LAK cell generation whereas no suppression was seen with the supernatants of the non-suppressive cell lines. Similarly, when supernatants from non-malignant cells (24h cultures of allogeneic endothelial cells obtained from human umbilical cord as previously described (Guillou et al., 1989) ) were added at concentrations as high as 20% or more, no suppression of LAK cell generation was observed. Thus, so far, we have found concordance between the LAK cell suppression seen with the tumour cells and that caused by the presence of their respective supernatants. Dose and time-related effects of tumour cell supernatants on LAK cell generation and proliferation Figure 1 represents the results of one representative experiment in which different concentrations of the tumour cell supernatant were present in the LAK generation cultures. It can be seen that concentrations of the COL0205 supernatant as low as 5% inhibited LAK cell generation and almost complete inhibition was observed with concentrations of 10 or 20%. Similar results were obtained with all the other suppressive cell line supernatants, maximum suppression being obtained with concentrations of 20%. In contrast, concentrations of supernatants from the non-suppressive cell lines had no effect on LAK cell generation at concentrations as high as 50% of the total culture volume. Figure 2 shows the effects of the COL0205 supernatant on the proliferation of these same IL-2 activated lymphocytes as assessed by the uptake of 3H-thymidine. Inhibition of lymphocyte proliferation was significantly diminished only at supernatant concentrations of 10% or more.
In Figure 3 it can be seen that the inhibitory effects of the tumour cell line supernatants were also temporally related.
Significant inhibition of LAK generation occurred only when the supernatant was present within the first 48 h of culture, there being no suppression when the addition of the supernatant was delayed until the third or fourth days of culture.
Effects of tumour cell supernatants on cytotoxic effector cell function in vitro The data shown in Figure 3 suggested that suppressive tumour cell supernatants have no effect on LAK cytotoxicity cultures at a concentration of 20%. LAK cytotoxicity was measured 4 days later and the data expressed as described in Table I . (Monson et al., 1986 (Monson et al., , 1987 . Furthermore, both clinically and experimentally, the administration of IL-2 alone (without adoptive cellular immunotherapy) fails to accomplish tumour regression suggesting that the suppressive mechanisms operative in man also exist in murine models (Mule et al., 1986a; Salup et al., 1986; Rosenberg et al., 1987 (Guillou et al., 1988) . Further studies are required to determine whether other cell lines of non-malignant or malignant origin cause similar effects.
The suppressor factor(s) does not directly inhibit cytotoxicity at the level of the effector cell as evidenced by the data shown in Table II . Furthermore in experiments not shown here, we have been unable to render the tumour target cells resistant to cytotoxicity by prior culture in the supernatant. Thus the tumour-derived factors do not appear to work in a manner analogous to that of the protective effects which interferons are able to exert on natural killer and LAK cell tumour targets (De Fries et al., 1988; Yeoman et al., 1988) . That prior treatment of the tumour cells with inhibitors of DNA, RNA and protein synthesis eliminates the inhibition of LAK cell induction observed in the presence of the tumour cell supernatants suggests that the suppressor factors are proteins coded for in the tumour genome. However, interference by virally encoded proteins cannot be excluded. Indeed, one such viral peptide, the retroviral envelope protein P15E, has been implicated in the suppression of lymphocyte proliferation . P15E perturbs monocyte function and directly inhibits T-lymphocyte proliferation (Harrell et al., 1986; Copelan et al., 1983) . Although P15E is normally only found in the envelope of lymphotropic or leukaemic viruses this peptide has been detected in murine B16 melanoma and is also expressed in lectinactivated lymphoblasts (Cianciolo et al., 1983 . It has been shown that monoclonal antibodies to P15E can prevent the suppressive effects of certain bovine tumour extracts on delayed hypersensitivity in vivo (Nelson et al., 1985) . As observed with the tumour supernatants reported herein, the suppressive effects of P15E are resistant to heating at 56°C.
In contrast, our preliminary crude estimate of the molecular weight of the factor(s) present in our supernatants indicate something in excess of 25 kD rather than the 15 kD of P1 5E.
More directly, however, although a synthetic peptide homologous to P1SE inhibits both spontaneous and interferon-boosted human NK activity, it has not been found to impair the activation of NK cells by IL-2 (Harris et al., 1987) .
A number of alternative candidate molecules for the supernatant suppressor factor described in our studies exist in the literature. Putnam & Roth (1985) have described a heat-stable, acid-labile glycoprotein derived from murine melanoma which can inhibit proliferative responses to lectins and IL-2. However, the molecular weight of this factor was only of the order of 10-12kD but was distinct from P15E. Pommier et al. (1987) and Ebert et al. (1987) have described a factor present in conditioned medium from HT-29 cells which was able to inhibit IL-2 production and lymphocyte proliferation and whose effects could not be prevented by the addition of further IL-2. The molecular weight of their factor was around 56 kD and because our factor(s) also appear to inhibit lymphocyte proliferation at higher concentrations the two may be identical. In our experiments the induction of LAK cell cytotoxicity was impaired at lower concentrations of supernatant than those required to inhibit proliferation, in keeping with previous suggestions that the in vitro induction of LAK cells is not dependent on DNA synthesis (Malkovsky et al., 1987) . This antiproliferative effect may have some in vivo significance, however, since experimentally IL-2 stimulates the proliferation of adoptively transferred LAK cells, the proliferation apparently being essential for therapeutic efficacy (Ettinghausen et al., 1985) . Mieschner et al. (1986) have also reported that gastrointestinal cancer cells and their products can also repress the proliferation of tumour infiltrating lymphocytes. Tumour cell lines derived from a variety of colorectal carcinomas appear to secrete both alpha and beta transforming growth factors (Coffey et al., 1986; Hanauske et al., 1987) , the latter having recently been described as a potent inhibitor of NK cell activity and murine LAK cell induction (Rook et al., 1986) . These growth factors might therefore represent potential candidates for the inhibitory substances present in our tumour cell supernatants. Whiteside et al. (1988) have experienced difficulty in generating proliferating lymphocytes from TIL extracted from metastatic head and neck and colorectal cancers. Even when so generated (following a lag period of some 30-40 days) such proliferating lymphocytes exert little or no cytolytic activity, suggesting that the suppressive effects seen in our in vitro experiments may also be operative in vivo. It is evident that caution must be exercised in extrapolating the results of these in vitro experiments to clinical in vivo circumstances. Nevertheless, it is tempting to speculate that the experiments we have described may lead to at least a partial explanation of the failure of IL-2 therapy to cause durable remission in patients suffering from advanced malignant disease. The relationship of the factors which we have observed to those described by others remains to be elucidated and we are currently attempting to characterise them in greater detail. However, if these studies succeed in demonstrating that such factors have in vivo relevance then their characterisation may result in the development of further strategies aimed at augmenting the clinical response rates to immunotherapy.
